Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City
– Live presentation and webcast to be held on
The meeting will feature presentations from leading PAH clinicians and
researchers along with Acceleron senior management, who will discuss the
current PAH treatment landscape and the importance of BMP signaling—a
molecular pathway fundamental to all forms of the disease. The Company
will highlight its latest preclinical research on sotatercept, its lead
product candidate in PAH, which will have been presented at the American
Heart Association Scientific Sessions on
Guest speakers include:
Aaron Waxman, M.D., Ph.D., Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital; Associate Professor of Medicine at Harvard Medical School Mark Rumbak, M.D., Professor of Medicine, Division Director of Pulmonary, Critical Care, and Sleep Medicine, University of South Florida
Attendance at the event is intended for institutional investors and research analysts. Please email email@example.com to RSVP in advance to attend, as space is limited.
Conference Call and Webcast
The live webcast will be accessible under "Events & Presentations" in the Investors/Media page of the Company's website at www.acceleronpharma.com.
Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to "Acceleron PAH R&D Deep Dive Event."
The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Sotatercept acts as a ligand trap for members of the transforming growth factor-beta superfamily, including those directly involved in the BMP pathway proven critical for maintaining healthy pulmonary vasculature. In multiple preclinical studies in PAH, sotatercept significantly decreased pulmonary vessel muscularization, improved pulmonary arterial pressures, and decreased indicators of right heart failure. Sotatercept is currently being evaluated in the PULSAR Phase 2 trial in PAH.
PAH is a rare, chronic, and rapidly progressing disorder characterized by the narrowing of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. PAH results in significant and progressive strain on the right side of the heart, often leading to limited physical activity, heart failure, and reduced life expectancy. The 5-year survival rate for patients with PAH is approximately 57%. Available therapies primarily act by promoting the dilation of pulmonary vessels without addressing the underlying cause of the disease. As a result, PAH often progresses rapidly for many patients despite standard-of-care treatment. A growing body of research has implicated imbalances in BMP and TGF-beta signaling as a primary driver of PAH in all forms of the disease.
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.
This press release contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company’s compounds and the expected timing for reporting of data from ongoing clinical trials. The words "anticipate," "believe," "could," "estimate," "expect," “goal,” "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results could differ materially from those included in the
forward-looking statements due to various risks and uncertainties,
including, but not limited to, that preclinical testing of the Company's
compounds and data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that the
development of the Company's compounds will take longer and/or cost more
than planned, that the Company or its collaboration partner,
The forward-looking statements contained in this press release are based on management’s current views, plans, estimates, assumptions and projections with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
Matt Fearer, 617-301-9557
Director, Corporate Communications